Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ioflupane I-123

FDA-approved product (solution, intravenous), marketed as Datscan, Ioflupane I-123.

Registered studies
36
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ioflupane I-123
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Abnormality of movement
  • Alzheimer disease
  • Computed tomography
  • Dementia
  • Lewy body dementia
  • Movement disorder
  • Multiple system atrophy
  • Neuroimaging measurement
  • Parkinson disease
  • Radiologic finding

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Iodine (123i) compounds
FDA pharmacologic class
Radioactive Diagnostic Agent FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA48.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli47.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae32.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis51.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

36registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ioflupane I-123 in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ioflupane I-123 with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Artificial Intelligence in Molecular Imaging: Predicting Parkinson's Risk in REM Sleep Behavior Disorder

    NCT06629207 · start 2024-10-07

    Registered record
    Registry ID
    NCT06629207
    Conditions
    Parkinson Disease; REM Sleep Behavior Disorder; Dementia, Lewy Body
    Interventions
    PET/CT with 18-FDG; SPECT : 123 I-FP-CIT (DATSCAN); MRI
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-10-07
    Completion
    2026-08-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease; REM Sleep Behavior Disorder; Dementia, Lewy Body
    InterventionPET/CT with 18-FDG; SPECT : 123 I-FP-CIT (DATSCAN); MRI
    PhaseNot applicable
    Registry statusRecruiting

  • [18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD

    NCT06120049 · start 2024-01-19

    Registered record
    Registry ID
    NCT06120049
    Conditions
    Parkinson Disease; Dementia With Lewy Bodies; MSA - Multiple System Atrophy; Alzheimer Disease
    Interventions
    [18F]-MFBG PET CT; [18F]-FE-PE2I PET CT or PET MRI; [123I]-MIBG SPECT CT; [18F]-MFBG PET dosimetry scans
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2024-01-19
    Completion
    2026-07
    Enrolment
    113

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease; Dementia With Lewy Bodies; MSA - Multiple System Atrophy; Alzheimer Disease
    Intervention[18F]-MFBG PET CT; [18F]-FE-PE2I PET CT or PET MRI; [123I]-MIBG SPECT CT; [18F]-MFBG PET dosimetry scans
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • DaTSCAN Brain Scintigraphy and Psychotropic Treatments: Influence on Radiotracer Binding

    NCT05683665 · start 2023-04-01

    Registered record
    Registry ID
    NCT05683665
    Conditions
    Parkinson Disease
    Interventions
    scintigraphy DaTSCAN
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-04-01
    Completion
    2023-07-01
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    Interventionscintigraphy DaTSCAN
    PhaseNot recorded
    Registry statusCompleted

  • Terazosin and Parkinson's Disease Extension Study

    NCT05109364 · start 2022-09-23

    Registered record
    Registry ID
    NCT05109364
    Conditions
    Symptomatic Parkinson Disease; REM Sleep Behavior Disorder; Pre-motor Parkinson's Disease
    Interventions
    Terazosin therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2022-09-23
    Completion
    2026-03-10
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSymptomatic Parkinson Disease; REM Sleep Behavior Disorder; Pre-motor Parkinson's Disease
    InterventionTerazosin therapy
    PhasePhase 2
    Registry statusActive not recruiting

  • Molecular and Functional Imaging in Monogenic PD.

    NCT05518617 · start 2022-07-01

    Registered record
    Registry ID
    NCT05518617
    Conditions
    Parkinson Disease; Nervous System Disorder; Neurodegenerative Diseases; Neurodegenerative Disease, Hereditary; Parkinson's
    Interventions
    Positron Emission Tomography (PET) scan using DASB tracer
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2022-07-01
    Completion
    2026-06-30
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease; Nervous System Disorder; Neurodegenerative Diseases; Neurodegenerative Disease, Hereditary +1 more
    InterventionPositron Emission Tomography (PET) scan using DASB tracer
    PhaseNot recorded
    Registry statusRecruiting

  • [18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor

    NCT04265209 · start 2021-12-01

    Registered record
    Registry ID
    NCT04265209
    Conditions
    Parkinson Disease; Essential Tremor
    Interventions
    SPECT; PET
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-12-01
    Completion
    2024-08-02
    Enrolment
    152

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease; Essential Tremor
    InterventionSPECT; PET
    PhasePhase 3
    Registry statusCompleted

  • A Study to Evaluate the Safety, Biodistribution, Internal Radiation Dosimetry, and Effective Dose of DaTSCAN™ Ioflupane (123I) Injection in Chinese Healthy Volunteers.

    NCT04564092 · start 2021-05-13

    Registered record
    Registry ID
    NCT04564092
    Conditions
    Healthy Subjects (HS)
    Interventions
    DaTSCAN™ Ioflupane (123I) Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-05-13
    Completion
    2021-09-04
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects (HS)
    InterventionDaTSCAN™ Ioflupane (123I) Injection
    PhasePhase 1
    Registry statusCompleted

  • Markers of Disease Progression and Gait Within the Parkinsonian Population

    NCT04653688 · start 2020-12-22

    Registered record
    Registry ID
    NCT04653688
    Conditions
    Parkinson Disease
    Interventions
    The FeetMe® Evaluation; the PKG® Watch,; MRI; DaTSCAN
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2020-12-22
    Completion
    2024-10-17
    Enrolment
    83

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionThe FeetMe® Evaluation; the PKG® Watch,; MRI; DaTSCAN
    PhaseNot applicable
    Registry statusCompleted

  • Terazosin Effect on Cardiac Changes in Early Parkinson's Disease

    NCT04386317 · start 2020-11-01

    Registered record
    Registry ID
    NCT04386317
    Conditions
    REM Sleep Behavior Disorder; Pre-motor Parkinson's Disease; Symptomatic Parkinson Disease
    Interventions
    Terazosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2020-11-01
    Completion
    2026-03-10
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionREM Sleep Behavior Disorder; Pre-motor Parkinson's Disease; Symptomatic Parkinson Disease
    InterventionTerazosin
    PhasePhase 2
    Registry statusActive not recruiting

  • A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients

    NCT04193527 · start 2020-06-28

    Registered record
    Registry ID
    NCT04193527
    Conditions
    Parkinsonian Syndrome; Parkinson Disease(PD); Multiple System Atrophy (MSA); Progressive Supranuclear Palsy (PSP); Essential Tremor
    Interventions
    DaTSCAN™ Ioflupane (123I) Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-06-28
    Completion
    2021-12-20
    Enrolment
    172

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinsonian Syndrome; Parkinson Disease(PD); Multiple System Atrophy (MSA); Progressive Supranuclear Palsy (PSP) +1 more
    InterventionDaTSCAN™ Ioflupane (123I) Injection
    PhasePhase 3
    Registry statusCompleted

  • Cardiac Changes in Early Parkinson's Disease: A Follow up Study

    NCT04218968 · start 2019-12-30

    Registered record
    Registry ID
    NCT04218968
    Conditions
    REM Sleep Behavior Disorder; Pre-motor Parkinson Disease; Symptomatic Parkinson Disease
    Interventions
    Carvedilol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2019-12-30
    Completion
    2026-06-30
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionREM Sleep Behavior Disorder; Pre-motor Parkinson Disease; Symptomatic Parkinson Disease
    InterventionCarvedilol
    PhasePhase 2
    Registry statusActive not recruiting

  • 123 I-FP-CIT SPECT Prescriptions for Parkinsonian Syndromes

    NCT05698784 · start 2019-06

    Registered record
    Registry ID
    NCT05698784
    Conditions
    Parkinson
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-06
    Completion
    2021-12
    Enrolment
    723

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease

    NCT03019757 · start 2018-08-30

    Registered record
    Registry ID
    NCT03019757
    Conditions
    Alzheimer's Disease; Lewy Body Dementia; Parkinson's Disease
    Interventions
    DaTscan; F18-AV-45; FDG-PET; APOE genotype; Polysomnogram; Clinical Assessment
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2018-08-30
    Completion
    2026-12
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer's Disease; Lewy Body Dementia; Parkinson's Disease
    InterventionDaTscan; F18-AV-45; FDG-PET; APOE genotype +2 more
    PhaseNot recorded
    Registry statusRecruiting

  • Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls

    NCT03675282 · start 2018-08-14

    Registered record
    Registry ID
    NCT03675282
    Conditions
    Parkinson Disease; REM Sleep Behavior Disorder; Healthy
    Interventions
    (11C)PE2I; Ioflupane
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2018-08-14
    Completion
    2024-04-23
    Enrolment
    82

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease; REM Sleep Behavior Disorder; Healthy
    Intervention(11C)PE2I; Ioflupane
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Identification of a Biomarker Predictive of Evolution of Parkinson Disease

    NCT03230526 · start 2018-04-16

    Registered record
    Registry ID
    NCT03230526
    Conditions
    Parkinson Disease
    Interventions
    [18F]DPA-714 PET scan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2018-04-16
    Completion
    2024-05-06
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    Intervention[18F]DPA-714 PET scan
    PhasePhase 2
    Registry statusUnknown